German life sciences firm Merck KGaA has celebrated the cornerstone ceremony of the Translational Science Center at its headquarters in Darmstadt, a 200 million-euro ($205 million) investment to accelerate science and innovation in healthcare.
This 30,000 m² fully integrated, multi-use building will include high-tech laboratories, a lecture hall, and office space allowing scientists from different disciplines to explore new avenues of research in fields ranging from identifying disease biomarkers to developing targeted therapies. The new facility is expected to be completed in 2025.
The Translational Science Center is part of the investment package of more than 1.5 billion euros at the global corporate headquarters in Darmstadt by 2025.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze